Products
Pre-Made Rilonacept Biosimilar, Fusion Protein targeting IL1B fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting IL-1/IL1-BETA/IL1F2/IL1beta for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-973
Pre-Made Rilonacept Biosimilar, Fusion Protein targeting IL1B fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting IL-1/IL1-BETA/IL1F2/IL1beta is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Rilonacept, sold under the brand name Arcalyst, is a medication used to treat cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome, and Muckle–Wells syndrome; deficiency of interleukin-1 receptor antagonist; and recurrent pericarditis.[1][2][3] Rilonacept is an interleukin 1 inhibitor.[4]
Rilonacept is a dimeric fusion protein consisting of the ligand-binding domains of the extracellular portions of the human interleukin-1 receptor component (IL-1R1) and IL-1 receptor accessory protein (IL-1RAcP) linked in-line to the fragment-crystallizable portion (Fc region) of human IgG1 that binds and neutralizes IL-1. Rilonacept is used to treat cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome, and Muckle–Wells syndrome; deficiency of interleukin-1 receptor antagonist; and recurrent pericarditis.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-973-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-973-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-973-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-973-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Rilonacept Biosimilar, Fusion Protein targeting IL1B fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting IL-1/IL1-BETA/IL1F2/IL1beta |
| INN Name | Rilonacept |
| Target | IL1B |
| Format | Fusion Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | Fusion - [IL1RAP (interleukin-1 receptor accessory protein) - IL1R1 (type 1 interleukin-1 receptor, interleukin 1 receptor, type I)]2 - IGHG1 Fc (Fragment constant) |
| VD LC | Fusion - [IL1RAP (interleukin-1 receptor accessory protein) - IL1R1 (type 1 interleukin-1 receptor, interleukin 1 receptor, type I)]2 - IGHG1 Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Regeneron Pharmaceuticals Inc. (Tarrytown NY USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
